Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
pVAXrcPSAv53l · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort I | EXPERIMENTAL | 50 µg DNA/dose, 3 patients |
| Cohort II | EXPERIMENTAL | 150 µg DNA/dose, 3 patients |
| Cohort III | EXPERIMENTAL | 400 µg DNA/dose, 3 patients |
| Cohort IV | EXPERIMENTAL | 1000 µg DNA/dose, 3 patients |
| Cohort V | EXPERIMENTAL | Optimal dose to be determined, 6 patients |
| Name | Type | Description |
|---|---|---|
| pVAXrcPSAv53l (DNA encoding rhesus PSA) | BIOLOGICAL | 5 doses, 4 weeks apart |
| DERMA VAX™ intradermal DNA delivery system | DEVICE | in vivo electroporation is applied after each DNA injection |
Inclusion Criteria: * Male patients. Age \>18 years. * HLA-A\*0201 positive. * Histologically confirmed prostate cancer. * Minimum two (2) and maximum four (4) years after treatment with curative or salvage radiotherapy. * Serum testosterone within normal range. * Increasing PSA from a previous ref...
Top 20 of 52 competitors
pVAXrcPSAv53l is an investigational DNA vaccine being studied for the treatment of prostate cancer. It is currently in Phase 1 clinical development. The drug is being evaluated in a dose-finding study that has been completed, with a total enrollment of 15 participants.
pVAXrcPSAv53l is a monoclonal antibody modality, though its specific molecular target is not disclosed in the available information. The drug is being investigated for its potential role in prostate cancer treatment, delivered via intradermal electroporation as part of a DNA vaccine approach.
pVAXrcPSAv53l is being developed by Pulse Biosciences, Inc, a company traded on the stock exchange under the ticker symbol PLSE. The company is conducting clinical research on this investigational drug for prostate cancer.
pVAXrcPSAv53l is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy in patients with prostate cancer.
pVAXrcPSAv53l has been studied in one clinical trial, identified as NCT00859729, titled "Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer." This Phase 1 trial was completed and enrolled 15 male participants aged 18 years and older in Sweden.
pVAXrcPSAv53l is a DNA vaccine, as indicated by its clinical trial description. The drug is delivered using intradermal electroporation, a technique that uses electrical pulses to enhance the uptake of the DNA vaccine into cells. It is being studied for prostate cancer.